H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Anavex Life Sciences (AVXL – Research Report) today and set a price target of $42.00. The company's shares closed last Thursday at $9.27, close to its 52-week low of $7.13. According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -45.5% and a 8.9% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Inovio Pharmaceuticals, and Aquestive Therapeutics. Anavex Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $39.00, implying a 348.8% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-anavex-life-sciences-avxl?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Anavex Life Sciences Charts.
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Anavex Life Sciences Charts.